Lepu and Hanx Biopharmaceuticals' Puyouheng (HX-008) Receive NMPA Approval for the Treatment of Solid Tumors
Shots:
- The NMPA has approved Puyouheng for patients with unresectable or MSI-H or dMMR advanced solid tumors incl. advanced colorectal cancers & other advanced solid tumors that have progressed prior to 1L therapy with no alternative treatment options
- The approval was based on a P-II study to evaluate Puyouheng (200mg, IV, q3w) in 100 patients with histologically confirmed MSI-H/dMMR advanced solid tumors. The results showed ORR for the ITT population was 49.0% with 9 cases of CR & 40 of PR at a median follow-up duration was 22.5mos.
- In the subgroup of patients with colorectal cancers who had failed prior triplet therapy, the ORR was 50.0% & was found to be safe & effective, patients also get benefit from the therapy
Ref: PRNewswire | Image: Lepu Biopharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
